Suche
Mein Konto
Billionaire Druckenmiller bets 93 million on healthcare stocks!
Stanley Druckenmiller invests $93.1 million in Eli Lilly and Viking Therapeutics, sells Nvidia and Palantir.
Billionaire Druckenmiller bets 93 million on healthcare stocks!
Stanley Druckenmiller, a prominent investor and billionaire, has made significant changes to his portfolio in recent weeks. Reported on November 8, 2025 Daily Hodl, that Druckenmiller has invested over $93 million in two stocks after fully divesting from Nvidia and Palantir.
In the third quarter of 2024, his Duquesne Family Office had already sold all Nvidia shares. The full exit from Palantir is planned by mid-2025. These moves indicate a clear shift in focus in Druckenmiller's investment strategy, particularly toward healthcare.
New investments in healthcare
As part of his recent investment decisions, Druckenmiller has substantially increased his holdings in Eli Lilly (LLY). He now holds 100,675 shares valued at approximately $78.5 million in the second quarter of 2025. Eli Lilly is considered a leader in the development of GLP-1 drugs used for weight loss and diabetes treatment, including the well-known drug Mounjaro.
In addition, he acquired 549,295 shares of Viking Therapeutics (VKTX), representing a value of approximately $14.6 million. Viking Therapeutics is clinical-stage and specializes in therapies for metabolic and endocrine disorders.
The associated financial assets that Druckenmiller manages are in excess of $4 billion. These developments could be a response to the growing demand for innovative healthcare solutions and indicate that Druckenmiller believes in the future of the healthcare sector.
Market analysis and outlook
The complete exit from Nvidia and Palantir demonstrates Druckenmiller's adaptability and willingness to move away from stagnating investments. The shift toward stronger healthcare and biopharma companies may reflect his belief that these sectors will play a significant role in the coming years.
Stanley Druckenmiller's current investments could therefore point the way to trends in the stock market. Analysts and investors could closely monitor this shift to understand how corporate healthcare strategies evolve and what impact this could have on the overall market.